Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndromes: early-phase trial registry
73 of 193 indexed Myelodysplastic Syndromes trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #55 of 28,707 conditions by registered trial count.
193 US clinical trials · 73 currently recruiting · #55 of 28,707 conditions by registered trial count
Myelodysplastic Syndromes: 193 US clinical trials tracked, 73 recruiting.
Myelodysplastic Syndromes is the subject of 193 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 148 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 13 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndromes
OPEN 73 | RECR 38% | LATE 11 | EARLY 148 | RANK #55 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Sclerosis (38% recruiting · 317 trials)
Myelodysplastic Syndromes lists 73 open slots (38% of 193 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndromes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndromes recruits in line with its size-band peers.
73 of 193 indexed trials (37.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Myelodysplastic Syndromes trials is spread across many organizations.
Washington University School of Medicine accounts for 13 of 193 trials (6.7%). 98 distinct sponsors appear on at least one study for this condition label.
-
Most Myelodysplastic Syndromes trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 174 trials that report a genuine target (sentinel values excluded). 118 of those (67.8%) plan for fewer than 100 participants.
-
Myelodysplastic Syndromes research is mostly interventional.
177 interventional and 16 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
193 total, page 1 of 4
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137643
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
NCT02269592
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137825
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
NCT01890486
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
National Cancer Institute (NCI)
NCT05350748
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
National Cancer Institute (NCI)
NCT05588154
HEME Home Transfusion Program
Dana-Farber Cancer Institute
NCT06487247
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
National Cancer Institute (NCI)
NCT07019155
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
University of Miami
NCT05745285
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Bristol-Myers Squibb
NCT05949684
Mosaic Trial for Stem Cell Transplant Recipients
Northwestern University
NCT06960993
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Washington University School of Medicine
NCT04986657
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology
NCT04256317
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems
NCT03802695
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
Dana-Farber Cancer Institute
NCT04968834
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Institut de Recherches Internationales Servier
NCT02074839
A Study of BGB-11417 in Participants With Myeloid Malignancies
BeiGene
NCT04771130
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Chordia Therapeutics
NCT05732103
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
NCT06499285
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Washington University School of Medicine
NCT04742634
A Telehealth Advance Care Planning Intervention
University of Rochester
NCT05875805
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
NCT06501196
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Takeda
NCT04419649
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Syntrix Biosystems
NCT04245397
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine
NCT05320198
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
NCT05362773
Study of REM-422 in Patients With AML or Higher Risk MDS
Remix Therapeutics
NCT06297941
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Montefiore Medical Center
NCT05342584
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Montefiore Medical Center
NCT05184842
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
GlaxoSmithKline
NCT06847867
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems
NCT07216443
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Children's Hospital of Philadelphia
NCT05194397
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics
NCT05473910
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
NCT05732961
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
NCT05088356
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
M.D. Anderson Cancer Center
NCT05365035
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
Washington University School of Medicine
NCT05434598
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT05805605
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT06047886
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
NCT04024761
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT03810196
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
GluBio Therapeutics
NCT06146257
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Masonic Cancer Center, University of Minnesota
NCT03579875
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Lixte Biotechnology Holdings
NCT03886662
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Masonic Cancer Center, University of Minnesota
NCT06594445
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Sawa Ito, MD
NCT06529731
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
NCT06113302
Ascorbate in Myelodysplastic Syndrome
Prajwal Dhakal
NCT07283900
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Montefiore Medical Center
NCT05986240
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
University of Illinois at Chicago
NCT06802315
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 80 |
| Phase 2 | 68 |
| Phase 3 | 9 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndromes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndromes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndromes page
193 registered trials, 73 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 73 Myelodysplastic Syndromes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Myelodysplastic Syndromes trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndromes condition card totals 193 registered trials; most-linked intervention Azacitidine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.